- Home
- CYAB vs ADIL Comparison
CYAB vs ADIL Comparison
Compare CYAB & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CYAB | ADIL |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 6.1M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | CYAB | ADIL |
|---|---|---|
| Price | $0.36 | $2.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $37.50 |
| AVG Volume (30 Days) | ★ 157.7K | 95.0K |
| Earning Date | 04-09-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.13 |
| 52 Week High | $2.99 | $5.17 |
Technical Indicators
Market Signals| Indicator | CYAB | ADIL |
|---|---|---|
| Relative Strength Index (RSI) | 33.67 | 52.98 |
| Support Level | N/A | $1.59 |
| Resistance Level | $0.50 | $2.98 |
| Average True Range (ATR) | 0.05 | 0.21 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 29.05 | 55.82 |
Price Performance
Historical ComparisonAbout CYAB Cyabra Inc. Common Stock
Cyabra Inc is an AI-powered SaaS company that detects and analyzes online disinformation. Its platform uses machine learning to monitor social media and news data in real time, identify fake accounts and harmful narratives, and assess content authenticity and sentiment.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.